Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Smith & Nephew PLC Director's Dealing 2023

Aug 14, 2023

4588_dirs_2023-08-14_64fd96b6-02d5-451f-88be-c4133f40531a.html

Director's Dealing

Open in viewer

Opens in your device viewer

National Storage Mechanism | Additional information

RNS Number : 2602J

Smith & Nephew Plc

14 August 2023

SMITH & NEPHEW PLC

14 AUGUST 2023

NOTIFICATION AND PUBLIC DISCLOSURE IN ACCORDANCE WITH THE REQUIREMENTS OF THE EU MARKET ABUSE REGULATION OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES ("PDMR") AND PERSONS CLOSELY ASSOCIATED WITH THEM.

1.   AWARDS MADE UNDER THE GLOBAL SHARE PLAN 2020

On 11 August 2023, the following awards of US$0.20 ordinary shares (the "Shares") in Smith & Nephew plc (the "Company") were granted under the Smith & Nephew Global Share Plan 2020. The awards have been made in London and are based on the closing Share price on the London Stock Exchange on 11 August 2023 of £11.24.

i.   PERFORMANCE SHARE PROGRAMME 2023 AWARD GRANTED UNDER THE SMITH & NEPHEW GLOBAL SHARE PLAN 2020

The Remuneration Committee has approved performance conditions attached to the vesting of this award, which are detailed below. This award will vest on 9 March 2026, subject to the achievement of the performance conditions which are measured over the period 1 January 2023 to 31 December 2025 as set out below.

The number of shares subject to the above awards are shown at target vesting. Should maximum vesting be achieved, the participant will receive 2x the number of shares shown below. The participant will receive an additional number of shares equivalent to the amount of dividend payable per vested share during the relevant performance period.

The following relates to the individual included in this section:

Reason for the notification
Initial notification /Amendment Initial notification
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
Name Smith & Nephew plc
LEI 213800ZTMDN8S67S1H61
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
Description of the financial instrument, type of instrument Smith & Nephew plc Ordinary Shares of USD 0.20 each
Identification code ISIN: GB0009223206
Nature of the transaction Performance Share Awards granted at target under the Smith & Nephew Global Share Plan 2020.
Date of Transaction 11 August 2023
Place of Transaction Grant took place outside a trading venue
Name (Position) Director / PDMR Price (£) Volume Aggregated information
Rohit Kashyap

(President Advanced Wound Management and Global Commercial Operations)
PDMR 11.24 47,339 N/A Single Transaction

The award made is subject to four equally weighted performance measures: Total Shareholder Return (TSR), Return on Invested Capital (ROIC), Global Revenue Growth and Cumulative Free Cash Flow. Page 138 of the 2022 Annual Report explains how TSR will be measured and defines the calculation of ROIC with reference to the methodology on page 136.

The award is subject to TSR as follows. Details of the two equally weighted peer groups are defined on page 138 of the 2022 Annual Report.

Award vesting as % of salary at date of grant
Sector based peer group FTSE100 peer group
Below the index Nil Nil
Equaling the index 8.6% 8.6%
8% above the index 34.4% 34.4%

Awards vest on a straight-line basis between these points. The maximum has been set significantly above target reflecting the maximum opportunity for outperformance.

The award is subject to ROIC as follows:

Return on Invested Capital

Year ended 31 December 2025
Award vesting as a % of salary
Below 8.5% Nil
8.5% 17.2%
9.5% 34.4%
10.5% 68.8%

Awards vest on a straight-line basis between these points.

The award is subject to Revenue Growth as follows:

Revenue Growth

Three years ended 31 December 2025
Award vesting as a % of salary
Below Threshold Nil
Threshold (-8% of target) 17.2%
Target - set by reference to our expectations 34.4%
Maximum or above (+8% of target) 68.8%

Awards vest on a straight-line basis between these points.

The award is subject to Cumulative Free Cash Flow as follows:

Cumulative Free Cash Flow

Three years ended 31 December 2025
Award vesting as a % of salary
Below Threshold Nil
Threshold (-20% of target) 17.2%
Target - set by reference to our expectations 34.4%
Maximum or above (+10% of target) 68.8%

Awards vest on a straight-line basis between these points.

Revenue Growth and Cumulative Free Cash Flow targets for the three years ended 31 December 2025 for this award, even though now determined, will not be disclosed until the 2025 Annual Report, when the Remuneration Committee will discuss performance against the targets. It is not possible to disclose precise targets at the time of grant to avoid giving commercially sensitive information to our competitors concerning our growth plans.

ii.    RETENTION SHARE AWARD GRANTED UNDER THE SMITH & NEPHEW GLOBAL SHARE PLAN 2020

Reason for the notification
Initial notification /Amendment Initial notification
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
Name Smith & Nephew plc
LEI 213800ZTMDN8S67S1H61
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
Description of the financial instrument, type of instrument Smith & Nephew plc Ordinary Shares of USD 0.20 each
Identification code ISIN: GB0009223206
Nature of the transaction Retention Share Award granted under the Smith & Nephew Global Share Plan 2020.
Date of Transaction 11 August 2023
Place of Transaction Grant took place outside a trading venue
Name (Position) Director / PDMR Price (£) Volume Aggregated information
Rohit Kashyap

(President Advanced Wound Management and Global Commercial Operations)
PDMR 11.24 69,604 N/A Single Transaction

One third of the above retention award will vest on 12 August 2024, a further third will vest on 11 August 2025 and the final third will vest on 11 August 206.  Each vesting is subject to Rohit Kashyap remaining in the employment of the Group on the date of vestings, not being under notice and have not achieved an "unsatisfactory performance" rating for his personal performance in the year prior to each vesting date

2.   TRANSACTIONS IN AMERICAN DEPOSITORY SHARES AS PARTICIPANTS OF THE COMPANY'S EMPLOYEE STOCK PURCHASE PLAN.

On 28 July 2023, Smith & Nephew plc (the "Company") received notification of the following transactions as detailed below.

Reason for the notification
Initial notification /Amendment Initial notification
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
Name Smith & Nephew plc
LEI 213800ZTMDN8S67S1H61
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
Description of the financial instrument, type of instrument Smith & Nephew plc SPON ADR American Depositary Shares (ADS)
Identification code ISIN: US83175M2052
Nature of the transaction Transactions in American Depository Shares as participants of the Company's Employee Stock Purchase Plan.
Place of Transaction New York Stock Exchange
Aggregated Information N/A Single Transactions
Name Director / PDMR Date of Transaction Nature of Transaction No. of ADS Price ($)
Bradley Cannon

(President Sports Medicine & ENT)
PDMR 21.05.2023 DRIP pursuant to 2022 final dividend payment 50.79925 32.0239
Mizanu Kebede

(Chief Quality and Regulatory Affairs Officer)
PDMR 21.05.2023

28.10.2022
DRIP pursuant to 2022 final dividend payment

DRIP pursuant to 2022 interim dividend payment
11.39024

4.16015
32.0239

23.7852
Deepak Nath

(Chief Executive Officer)
Director 21.05.2023

11.01.2023
Purchase

DRIP pursuant to 2022 final dividend payment
6.30779

446.90726
32.0239

22.86
Paul Connolly

(President Global Operations)
PDMR 21.05.2023

11.01.2023
DRIP pursuant to 2022 final dividend payment

Purchase
4.76051

446.90726
32.0239

22.86
Scott Schaffner

(President Sports Medicine)
PDMR 21.05.2023 DRIP pursuant to 2022 final dividend payment 27.20031 32.0239
Alison Parkes

(Chief Compliance Officer)
PDMR 21.05.2023 DRIP pursuant to 2022 final dividend payment 14.683.72 32.0239

* including those held by Persons Closely Associated with the Director/PDMR. All figures in these columns are stated to 5 decimal places where applicable.

3.   PURCHASE OF ORDINARY SHARES THROUGH THE COMPANY'S DIVIDEND RE-INVESTMENT PLAN FOLLOWING THE 2022 INTERIM DIVIDEND PAYMENT ON 26 OCTOBER 2022

Reason for the notification
Initial notification /Amendment Initial notification (Note: late notification)
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
Name Smith & Nephew plc
LEI 213800ZTMDN8S67S1H61
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
Description of the financial instrument, type of instrument Smith & Nephew plc SPON ADR American Depositary Shares (ADS)
Identification code ISIN: US83175M2052
Nature of the transaction Purchase of ordinary shares through the Company's Dividend Re-Investment Plan following the 2022 interim dividend payment
Date of Transaction 2022 - 10 - 26
Place of Transaction London Stock Exchange
Name Director / PDMR Price Volume Aggregated information
Helen Barraclough

(Group General Counsel and Company Secretary)
PDMR £10.01893 302.8665 N/A Single Transaction

Sarah Carne  

Deputy Company Secretary

Smith & Nephew plc

Tel:  +44 (0)1923 477100

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHFLFFVTFISLIV